First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases.
about
Autoimmune diseases: Inhibitor of adaptor protein shows self-antigen selectivity.Selected signalling proteins recruited to the T-cell receptor-CD3 complex.Integrated analysis of B‑cell and T‑cell receptors by high‑throughput sequencing reveals conserved repertoires in IgA nephropathy.A non-conserved amino acid variant regulates differential signalling between human and mouse CD28.Development of a screening strategy for new modulators of T cell receptor signaling and T cell activation.NCK-dependent pericyte migration promotes pathological neovascularization in ischemic retinopathy
P2860
First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases.
@en
type
label
First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases.
@en
prefLabel
First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases.
@en
P2093
P2860
P50
P1476
First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases
@en
P2093
Alberto Orfao
Aldo Borroto
Almudena Perona
Ana Martinez-Riaño
Antonio Morreale
Balbino Alarcon
Beatriz Moreno
Clara L Oeste
Cristina Prieto
David Abia
P2860
P304
P356
10.1126/SCITRANSLMED.AAF2140
P407
P50
P577
2016-12-01T00:00:00Z